BLTE — Belite Bio, Inc

Summary of Belite Bio (BLTE) Q1 2026 Earnings Call

1. Key Financial Results and Metrics

• R&D Expenses: Increased to $15.7 million from $9.4 million in Q1 2025, driven by the Dragon 2 trial and higher manufacturing costs.
• Non-GAAP R&D Expenses: $13.8 million compared to $7.4 million in Q1 2025.
• SG&A Expenses: Rose to $17 million from $6.1 million in Q1 2025, primarily due to increased compensation and professional fees.
• Non-GAAP SG&A Expenses: $5.7 million compared to $1.5 million in Q1 2025.
• GAAP Net Loss: $26.9 million, up from $14.3 million year-over-year.
• Non-GAAP Net Loss: $13.7 million compared to $7.6 million in Q1 2025.
• Cash Position: Ended Q1 with $799 million in cash and equivalents, providing a strong financial foundation for ongoing projects.

2. Strategic Updates and Business Highlights

• NDA Submission: Initiated rolling submission to the FDA for Stargardt disease, expected to complete by Q2 2026.
• Commercial Preparations: Hired commercial leadership and expanded teams in sales, market access, and medical affairs.
• Clinical Trials: Completed enrollment in the Phase 2/3 Dragon 2 trial for Stargardt disease, involving 73 adolescents and adults across Japan, the U.S., and the UK.
• Market Engagement: Actively engaging with the retinal community to raise awareness of Stargardt disease and the upcoming treatment.

3. Forward Guidance and Outlook

• FDA Approval Timeline: Anticipating FDA approval for Stargardt disease treatment in early 2027, with a quick launch post-approval.
• Patient Estimates: Aiming to provide estimates on the number of patients who could receive treatment in 2027 during a commercial event in September.
• Operational Expenses: Expected to increase as the company ramps up for commercialization, but remains manageable given the strong cash position.

4. Bad News, Challenges, or Points of Concern

• Increased Losses: Significant year-over-year increase in net losses raises concerns about the sustainability of current spending levels.
• Regulatory Uncertainty: While the FDA has indicated a potential path for approval, there is still uncertainty regarding the necessity of additional data from the Dragon 2 trial.
• Market Awareness: Although there is enthusiasm for Tinlarebant, awareness among retinal specialists remains limited, indicating a need for further education and outreach efforts.

5. Notable Q&A Insights

• FDA Communication: The company has had discussions with the FDA regarding the Dragon 1 study, indicating a possibility of approval based on existing data without needing Dragon 2 results.
• Commercial Strategy: Plans to establish two teams focused on diagnostics and drug promotion, targeting retina specialists and patient advocacy groups.
• Pricing Strategy: Preliminary discussions with payers suggest support for a pricing range of $350,000 to $500,000, reflecting the strong unmet need for treatment.
• Geographic Expansion: The company plans to align international filings with the FDA submission timeline, prioritizing the U.S. market initially.

Overall, Belite Bio is making significant strides in its clinical and commercial preparations, backed by a robust financial position, but must navigate regulatory uncertainties and market awareness challenges as it approaches the launch of its Stargardt disease treatment.